Abstract
Purpose :
To investigate the effect of collagen type II, alpha1 peptide (G-Q-D-G-L-A-G-P-K) on experimental choroidal neovascularization (CNV) and human umbilical vein endothelial cell tube formation.
Methods :
Tube formation was assayed in VEGF induced Ea.hy-926 cell cultures in matrigel. CNV was induced in C57BL/6 mice by laser photocoagulation (4 spots per eye, 532 nm, 240 mW, 0.1 sec duration, 50 μm spot size). Mice were divided into four groups: control group (intravitreal injection of PBS only, n=5), CNV group (laser and PBS injection, n=10), positive control group (laser and 5 μg of avastin injection, n=10) and CPII group (laser and 5 μg of CPII injection, n=10). Intravitreal injections of avastin and CPII were performed for 5 days starting at day of laser injury. Two week after laser treatment, size of CNV was quantified by retina/choroid flat mounts labeled with 25 mg/ml fluorescein isothiocyanate (FITC)-dextran. The angiogenic factors expression in retina/choroid complex were determined by western blot analysis.
Results :
CPII at the concentration of 200 μg/ml decreased the number of formed capillary tubes in response to vascular endothelial growth factor. Two weeks after laser photocoagulation, Intravitreal injection of CPII significantly decreased the size of the CNV lesions compared with vehicle (PBS) injections. The expression levels of vascular endothelial growth factor, VEGFR-1, -2 and angiopoietin 2 in retina/choroid complex were increased after laser photocoagulation. However, the expression of these angiogenic factors were suppressed by collagen type II, α1 peptide.
Conclusions :
Collagen type II, α1 peptide demonstrated anti-angiogenic properties in human umbilical vein endothelial cell and mouse model of CNV. Therefore, CPII is possible promising material for treatment of choroidal neovascularization.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.